| BIOVAXYS TECHNOLOGY CORP. |
| Kanada |
| Gesundheit |
| CA09076M2004 / A41C58 |
| 5LB0 (Frankfurt) |
| FRA:5LB0, ETR:5LB0, 5LB0:GR |
| - |
| https://www.biovaxys.com/ |
|
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. It leverages its proprietary DPX™ immune-educating delivery technology platform alongsi..
>Volltext.. |
| 1.27 Mio. EUR |
| 1.35 Mio. EUR |
| - |
| -3.07 Mio. EUR |
| -3.78 Mio. EUR |
| -0.14 EUR |
| 0.08 Mio. EUR |
| - |
| -1.86 Mio. EUR |
| - |
| - |
| -17.07% |
| - |
| - |
| - |
| - |
| BIOVAXYS |
| 05.04.26 |
|